CrossMark

AUTHOR CORRECTION

Author Correction: Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study

Jelica Bjekić-Macut · Teodora Beljić Živković · Radivoj Kocić

Author Correction to: Diabetes Ther
https://doi.org/10.1007/s13300-018-0378-4

In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the 'Discussion' section was incorrectly published.

The sentence "…was similar (3100.314 ± 110.1298 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)".

Should actually say "…was similar (0.31 ± 0.12 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)".

J. Bjekić-Macut
Belgrade School of Medicine, Bezanijska Kosa University Medical Center, Division of Endocrinology, Diabetes and Metabolic disorders, University of Belgrade, Belgrade, Serbia

T. B. Živković (✉)
Belgrade School of Medicine, "Zvezdara" University Medical Center, Division of Endocrinology, Diabetes and Metabolic disorders, University of Belgrade, Belgrade, Serbia
e-mail: dorabeljic@beotel.net

R. Kocić
Clinic for Endocrinology, Faculty of Medicine, University of Nis, Nis, Serbia